gastroesophageal reflux disease
Conditions
Interventions
control group:Tegoprazan for 8 weeks
experimental group:Cidine in combination with Tegoprazan for 8 weeks
Sponsors
The Seventh Affiliated Hospital, Sun Yat-sen University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Willing to sign informed consent; Meeting the diagnosis of gastroesophageal reflux disease: patients with typical symptoms such as heartburn and reflux, meeting the diagnosis of GERDQ questionnaire or proton pump inhibitor diagnostic therapy for 2 weeks, or atypical symptoms but reflux confirmed by 24-hour esophageal PH+ impedance monitoring; Endoscopic evidence of reflux; Ages 18 to 75, gender unlimited; The course of the disease is more than 6 months; Patients with ineffective oesophageal motility were diagnosed according to manometry for oesophageal motility disorders (4th edition Chicago Classification).
Exclusion criteria
Exclusion criteria: Autoimmune diseases affecting gastrointestinal motivity, such as scleroderma, dermatomyositis, and central or peripheral nervous system diseases, after cardiac radiofrequency ablation, etc; High resolution esophageal manometry ruled out diffuse esophageal spasm, achalasia of cardia, EGJ outflow tract obstruction; Gastroscopy to rule out organic diseases of the stomach and esophagus (such as esophageal cancer); History of gastric or esophageal surgery, including patients after endoscopic or laparoscopic fundoplication; Serious complications (such as uncontrolled hypertension, gastrointestinal bleeding, severe cardiopulmonary, liver, kidney, hematopoietic diseases, etc.); Severe comorbiditions (such as uncontrolled hypertension, gastrointestinal bleeding, severe cardiopulmonary, liver, kidney, hematopoietic diseases, etc.) can not stop alcohol abuse during the study period (equivalent to alcohol dose =40g/day for men and =20g/day for women); Pregnant women who are breastfeeding or women whose pregnancy is not ruled out; Known allergy to this ingredient; The researchers found it unsuitable for participants.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| DCI LES;Lower esophageal sphincter (LES);Healing of esophageal mucosa; | — |
Secondary
| Measure | Time frame |
|---|---|
| Symptoms of patients with gastroesophageal reflux disease;Quality of life in patients with gastroesophageal reflux disease; | — |
Countries
China
Contacts
Public ContactJian Qi
The Seventh Affiliated Hospital, Sun Yat-sen University
Outcome results
None listed